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Background: Sputum induction is a non-invasive method for obtaining measurements of inflammation in the airways.
Whether spontaneously sampled sputum can be a valid surrogate is unknown. The aim of this study was to compare
levels of six inflammatory markers in sputum pairs consisting of induced and spontaneous sputum sampled on the
same consultation either in a stable state or during exacerbations of chronic obstructive pulmonary disease (COPD).
Methods: 433 COPD patients aged 40–76, Global initiative for chronic Obstructive Lung Disease (GOLD) stage II-IV were
enrolled in 2006/07 and followed every six months for three years. 356 patients were followed for potential exacerbations.
Interleukin-6, interleukin-8, interleukin-18, interferon gamma-inducible protein-10, monokine induced by gamma
interferon and tumor necrosis factor-alpha (IL-6, IL-8, IL-18, IP-10, MIG and TNF-α) were measured by bead based multiplex
immunoassay in 60 paired sputum samples from 45 patients. Albumin was measured by enzyme immunoassay, for
concentration correction. Culturing for bacterial growth was performed on 24 samples. Bland-Altman plots were used to
assess agreement. The paired non-parametric Wilcoxon signed-rank test, the non-parametric Spearman’s rank correlation
test and Kruskal-Wallis test were used for statistical analyses. For all analyses, a p-value < 0.05 was considered significant.
Results: Agreement between the two measurements was generally low for all six markers. TNF-α was significantly higher
in spontaneous sputum at exacerbations (p = 0.002) and trending higher at the steady state (p = 0.06). Correlation
coefficients between the levels of markers in induced and spontaneous sputum varied between 0.58 (IL-18) to 0.83
(IP-10). In spontaneous sputum IL-18 and MIG were higher in ex-smokers (p < 0.05). The levels of all markers were higher
in GOLD stage III & IV except for IL-6 in spontaneous sputum and IL-18 in induced sputum, compared with GOLD stage II,
although not statistically significant. In spontaneous sputum the levels of IL-6 were significantly higher if Haemophilus
influenzae (HI) was not cultured.
Conclusion: We observed a low agreement and significant differences in inflammatory markers between induced and
spontaneous sputum, both at steady state and exacerbations. We recommend considering sampling method when
reporting on inflammatory markers in sputum.
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Chronic obstructive pulmonary disease (COPD) is a
chronic inflammatory disease affecting both the airways
and lung parenchyma [1]. The increased airway inflam-
mation has been well described, but its role is yet
controversial [2]. Obtaining reliable measurements of
airway inflammation non-invasively can enable large
cohort studies. Biomarkers sampled by methods like
exhaled breath condensate and induced sputum have
been compared recently [3]. Induced sputum sampling
(ISS) is a non-invasive procedure, which has been standard-
ized and used extensively the last 20 years [4]. Nebulized
and inhaled saline increases sputum production in the
lungs [4]. Induction has been reported to provide sputum
samples of sufficient quality for analyses in more than 80%
of asthma and COPD patients [5-8]. In patients with ob-
structive lung disease, ISS is usually performed in the steady
state as it can induce bronchoconstriction [9,10]. However,
at least one study has shown that it can be done safely also
during exacerbations in patients with mild to moderate
COPD [11].
An alternative to ISS is spontaneous sputum sampling
(SSS). Levels of inflammatory markers and cell counts in
spontaneous and induced sputum have been presented
without discriminating between the two sampling methods
in some studies [12-14]. Two studies have found that cell
viability was higher in induced than spontaneous sputum
in patients with asthma or COPD [15,16]. However, few
studies have addressed whether induced and spontaneous
sputum sampled from patients with COPD can actually be
used interchangeably for analyses of inflammatory markers,
as it was pointed to in a review article published as late as
in 2013 [17]. More studies on the subject were recom-
mended already in 2002 [4].
The aim of this study was to compare the levels of the
six common inflammatory markers interleukin 6, 8 & 18
(IL-6, IL-8 IL-18), interferon gamma-inducible protein-
10 (IP-10), tumor necrosis factor-alpha (TNF-α) and
monokine induced by gamma interferon (MIG) in paired
induced and spontaneous sputum samples collected
from COPD patients in the stable state and/or during
acute exacerbations. These markers were chosen for dif-
ferent roles in airways inflammation in COPD, as part of
the analyses in the Bergen COPD Exacerbation Study. In
addition, this study allowed for an assessment of the




The Bergen COPD Cohort Study (BCCS) was a three
year follow-up of 433 COPD patients from western
Norway between 2006 and 2010, previously described in
detail [18]. The patients were invited to our study centreevery six months, and sputum induction was performed
at nearly all visits. Of the 433 COPD patients, 356
patients living in a proximity that meant they belonged
to the Bergen hospital district were offered concomitant
participation in the Bergen COPD Exacerbation Study
(BCES). Patients included in the BCES were given a lam-
inated green-card with detailed instructions regarding
potential symptoms of COPD exacerbations and a tele-
phone number to our study nurse. The telephone was
open 12 hours per day, seven days a week for the three
years the study lasted. Once contact had been made, the
study nurse determined whether immediate hospitalization
was necessary, or whether a visit with a study physician
could be scheduled the next working day. During that visit
or at the ward the day after hospitalization, sputum induc-
tion was attempted if our study physician determined the
event to be a clinical COPD exacerbation, with a formal
assessment according to Wedzicha and Donaldsons’s defin-
ition [19].
Spontaneous sputum samples were collected before
the induced sputum sample at the same time point at
occasions when the patients presented with abundant
sputum. In total 60 sputum pairs of acceptable quality
from 45 patients in the stable state (n = 31) or during
COPD exacerbation (n = 29) were available for analysis.
Classification into Global initiative for chronic Obstructive
Lung Disease (GOLD 2007) stage and information on
smoking habits, were based on the baseline visit in the
BCCS. All patients provided written informed consent,
and both studies were approved by the Norwegian
Regional Ethical Committee.
Sputum sampling and processing
Inductions were performed using an ultrasonic wave
nebulizer. Hypertonic saline (3%) was inhaled seven
minutes times three, and sputum was attempted sam-
pled after each inhalation. If however, the patient was
evaluated by the study physician as being too clinically
obstructive, or if the patient did not want to inhale an
increased saline concentration, the physiological saline
concentration of 0.9% was inhaled instead. Of the 60
sputum pairs evaluated, induction was done with 3%
saline in 47 cases, 0.9% in ten cases, while for three
inductions the concentration was not recorded. Spiromet-
ric evaluations (Vitalograph S-model Vitalograph Ltd.,
Buckingham, England at regular visits in the steady state,
EasyOne model 2001 Ndd Medizintechnik AG, Zurich,
Switzerland at exacerbation visits) were performed after in-
halation of 200–400 ug salbutamol prior to induction with
saline. Spirometry was then repeated after each inhalation
of the saline. The procedure ended if FEV1 declined 20% or
more, if the patient’s symptoms worsened, or if the patient
did not wish to proceed. If the patient’s post-bronchodilator
oxygen saturation was <90%, induction was not performed.
Tangedal et al. Respiratory Research 2014, 15:138 Page 3 of 8
http://respiratory-research.com/content/15/1/138For the SSS, patients were asked to expectorate in two
different cups, and the most purulent sputum was proc-
essed. Both types of sputum samples were kept on ice until
processed for quality control and storage, usually within
30 minutes. To break disulphide bonds in mucin, 4 ml di-
thiothreitol 0.1% (DDT) per gram sputum were added [20].
The samples were then homogenized using an Eppendorf
homogenizer at 600 rpm for 15 minutes at a temperature of
4 degrees Celsius. Phosphate-buffered saline (PBS) was
added, and the sample filtered to increase homogenization.
Supernatants were removed after 15 minutes centrifugation
at 4 degrees Celsius, 450 g, aliqouted in 0.5 ml tubes, and
stored at −80 degrees Celsius. Trained personnel evaluated
viability after staining with tryptan blue. For the sputum
samples to be considered of acceptable quality there had to
be > 1 million/mL cells, < 20% epithelial cells and the leuco-
cyte viability had to be > 30%. After December 2006, all
sputum samples were also cultured at the Department of
Microbiology, Haukeland University Hospital.
The sputum samples were analysed for cytokines using
the Luminex® xMAP® technology (Luminex Corporation,
Austin, Texas). The cytokine assay used was made by com-
bining standards from BioRad (Bio-Plex Pro Human Cyto-
kine Standards Group I 27-Plex #171-D50001, Lot No
5022130. Bio-Plex Pro Human Cytokine Standards Group
II 23-Plex #171-D10502 Lot No 5015357) and singleplex
assays containing beads for analyses of IL-6, IL-8 IL-18, IP-
10, TNF-α and MIG. Thus, all six markers were analyzed
in simplex. The samples were processed on a Luminex 100
instrument and the results collected and stored by STarSta-
tion software version 2.0 (STarStation Software Version
2.0, Applied Cytometry, Sheffield, UK.) The procedure was
performed according to the manufacturer’s instructions on
six separate days in September 2011.
For 58 of the 60 sputum pairs we also had enough
material to perform an enzyme immunoassay of levels of
albumin in duplex (Albumin Human ELISA kit, ab
108788, Abcam, Cambridge, UK). Albumin was used as a
correction factor for concentration differences between the
induced and spontaneous sample for each pair in the
following way: The induced to spontaneous albumin ratio
was calculated for each sputum pair, and the level of each
of the six markers in each of the spontaneous sputum sam-
ples multiplied by the corresponding ratio. All later statis-
tical analyses were performed both on “corrected” sputum
levels and “uncorrected” sputum levels.
Statistical analyses
Stata 12.0 was used for the statistical analyses (StataCorp.
College Station, Texas). Bland-Altman plots were made to
assess agreement between the measured levels of the
markers in induced and spontaneous sputum pairs. Bland
& Altman advocates using the difference between the two
measurements as the central measurement of bias, and thespread of the difference as a measure of limits of agreement
[21]. Usually the difference between the measurements is
plotted against the mean of the two measurements, with 2
standard deviations (SD) of the difference representing the
95% limits of agreement. However, sometimes the differ-
ence is dependent upon the size of the mean, in which
Bland & Altman advocates plotting on a log scale [22]. This
was the case for all six markers in our study.
The inflammatory markers were not normally distrib-
uted, hence the paired non-parametric Wilcoxon signed-
rank test was used to compare levels of the markers and
cell viability between spontaneous and induced sputum.
For correlation analyses between spontaneous and
induced samples the non-parametric Spearman’s rank
correlation test was used. For comparisons of the levels of
inflammatory markers by clinical characteristics, Kruskal-
Wallis test was used. For comparisons of FEV1 decline
between stable state and exacerbations during inductions,
Wilcoxon signed-rank test was used. For all analyses, a
p-value of less than 0.05 was considered significant.
Results
The characteristics of the study population are presented
in Table 1. 60 sputum pairs were available from 45
patients, of which 15 of the patients were women. Of the
60 sputum pairs, 31 were sampled during the stable state
and 29 during COPD exacerbations (Table 1).
Mean cell viability was 98% for both the induced and
spontaneous sputum samples. Among the induced sam-
ples, 2 out of 60 samples had viability below 90%, for the
spontaneous samples all were 90% viable or better.
Of the six inflammatory markers, TNF-α was signifi-
cantly higher when measured in spontaneous sputum
during exacerbations and almost reaching statistical sig-
nificance in the steady state (Table 2). For the other
markers, no clear trend was seen (Table 2).
Bland-Altman plots for all six inflammatory markers on
the log scale are presented in Figure 1. To obtain the
limits of agreement the antilog of the two standard devia-
tions were calculated, and these are presented in Table 3
together with the Spearman’s rank correlation coefficients.
Although the correlation was fair, varying between 0.58
for IL-18 to 0.83 for IP-10, the agreement was quite low
for all six inflammatory markers. Since the 95% limits of
agreement were calculated on the log scale, the upper and
lower limits represents ratios relative to one. Thus, based
on the calculations presented in Table 3, one would expect
the measurement of for instance IL-6 in spontaneous spu-
tum to fall between 6 times higher or 8 times lower than
that measured in induced sputum 95% of the time.
Even though agreement between individual measure-
ments was low, there could be value to the spontaneous
samples if the levels of the markers showed the same asso-
ciations to clinical parameters in spontaneous as in the
Table 1 Characteristics of the study population
n %
Patients 45











Patients with one sputum pair** 36 80
Patients with multiple sputum pairs 9 20
Sputum pairs 60
stable state 31 52





**Consisting of one spontaneous and one induced sputum sample.
†Detected in induced and/or spontaneous sputum sampled from stable state
visits, and/or exacerbations.
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measured levels of the inflammatory markers in spontan-
eous and induced samples, and clinical variables are pre-
sented in Table 4. There was no consistent difference in
levels of any of the six markers between current and ex-
smokers. However, in the spontaneous samples the mea-
sured levels of IL-18 and MIG were significantly higher in
ex-smokers, an association not found in the inducedTable 2 A comparison of inflammatory markers in induced an
at the time; either during a COPD exacerbation or during the





IL-6(pg/ml) median, IQR 10.0(4.9-26.6) 10.4(2.8-23.3)











*Wilcoxon sign rank test.samples. For all markers except IL-6 and IL-18, there was
a non-significant trend of higher levels in GOLD stage III
& IV compared with GOLD stage II. Importantly however,
the pattern was the same for both spontaneous and in-
duced sputum samples. Finally, in the 24 sputum pairs
where culture was obtained, we examined which impact
Haemophilus influenzae (HI) had on the pattern of the
sputum markers. In the spontaneous samples HI was as-
sociated with significantly lower levels of IL-6, a difference
not found in the induced samples. In addition, we
observed that in the spontaneous samples levels of MIG
were lower in sputum with HI, whereas the opposite
pattern was seen in the induced samples (Table 4).
To assess the safety of induction during exacerbations
and the stable state we calculated the decline in FEV1%
predicted during induction for all COPD patients who
underwent inductions both in the BCCS and BCES. For
decline in FEV1% predicted from post bronchodilation
values during induction the relative fall was calculated
(thus a fall from 30% predicted to 20% predicted will be
presented as a 33% decline). To avoid repeated measure-
ments from the same patient at steady state and/or at
exacerbations only one registered induction at the two
different disease states was selected for analyses per pa-
tient. 63 patients were induced during exacerbation. 33
of the patients were GOLD stage III or IV, while the
remaining 30 were GOLD stage II. We found no signifi-
cant difference in FEV1% predicted decline caused by
induction related to disease severity (p = 0.07) during
exacerbations. When comparing patient groups in the
stable state we found that patients with more severe
COPD had a statistically larger decline related to induction,
than patients with COPD GOLD stage II (p < 0.001). The
relative fall was significantly higher during the stable state
than during exacerbations (p = 0.03) (Table 5). However,
no adverse events followed inductions regardless of disease
state and severity, and all patients increased in FEV1 after a
rest period and a new inhalation of salbutamol.d spontaneous sputum sampled from the COPD patients
stable state






0.29 20.5(6.11-43.2) 13.9(2.2-55.2) 0.46
0.77 514.2(225.6-1257.2) 3709.9(171.7-976.7) 0.18
0.15 529.0(215.4-2554.8) 362.3(142.0-1393.1) 0.07
0.002 0.9(0-2.4) 1.3(0.2-4.3) 0.06
0.52 6.5(2.4-25.6) 9.6(0.8-18.2) 0.64
0.41 534.4(56.9-1450.1) 567.4(178.0-2031.7) 0.82
Figure 1 Bland-Altman plots of the agreement between measurements of six inflammatory markers in induced and spontaneous
sputum samples.
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This study showed that for the six inflammatory
markers, the correlation between levels measured in
induced and spontaneous sputum pairs was fair, but the
agreement was quite low. TNF-α was significantly higher
in spontaneous sputum samples than in induced samples
when measured during a COPD exacerbation. Further,
there was a relationship between HI carrier state and IL-
6, and smoking status and IL-18 and MIG, found only in
spontaneous sputum samples.
There are some methodological issues to consider.
Firstly, it has been shown that both PBS and DTT affect
the recovery of some cytokines [12,23]. However, a
strength of this study was that the exact same processing
protocol was used for all sputum pairs, and this shouldTable 3 Rank correlation coefficients and the 95% limits of ag








*Spearman’s rank correlation test.
†±2 SD of the mean difference between the two measurements.thus not impact the measured levels differently between
spontaneous and induced sputum samples. Secondly, all
the inflammatory markers were measured in simplex,
thus the potential measurement error is greater than if
the markers were measured in duplex. The choice of
analysing in simplex was due to cost, since this is part of
a larger analysis of inflammatory markers in sputum.
Most importantly however, all sputum pairs were analysed
on the same plate, on the same day. Thus the measure-
ment error should not differ between spontaneous and in-
duced samples. Thirdly, we found associations between
inflammatory markers and smoking, and inflammatory
markers and colonization with HI only in spontaneous
sputum. We found no association between inflammatory
markers and GOLD stage in either type of sputum, butreement between measurements of six inflammatory








Table 4 Median (IQR) values of inflammatory markers in induced and spontaneous sputum samples by smoking, GOLD stage and H. influenzae carrier state
Smoking status GOLD stage H. influenzae
Current smoker n = 15 Ex-smoker n = 29 p* II n = 15 III+IV n = 29 p* No n-12 Yes = n = 12 p*
IL-6(pg/ml)
induced 17.2(5.7-36.2) 16.7(4.0-43.2) 0.63 16.7(4.5-67.8) 19.4(5.2-36.2) 0.78 20.7(10.9-49.0) 17.8(1.3-28.6) 0.16
spontaneous 10.2(3.0-29.5) 21.5(5.8-48.2) 0.22 15.6(2.2-64.9) 13.8(4.45.8) 0.79 32.2(22.4-75.38) 12.0(2.6-18.8) 0.01
IL-8(pg/ml)
induced 505.4(161.3-805.9) 517.0(193.3-1257.2) 0.54 233.4(170.0-1257.2) 529.0(224.5-1156.0) 0.37 277.6(170.0-649.0) 655.49(274.70-832.70) 0.32
spontaneous 221.0(165.4-674.4) 405.0(173.2-891.8) 0.42 210.1(112.7-844.1) 546.3(174.7-891.8) 0.18 336.9(210.1-734.2) 570.4(265.8-1141.4) 0.23
IP-10(pg/ml)
induced 216.5(130.9-826.2) 624.3(289.9-1844.9) 0.08 232.5(175.2-748.3) 600.8(216.7-1844.9) 0.20 477.5(175.2-2554.8) 696.1(56.0-1574.1) 0.85
spontaneous 345.6(124.9-716.5) 461.0(237.5-1361.7) 0.14 354.5(129.7-780.1) 448(237.5-1202.0) 0.33 491.9(285.2-2269.7) 582.7(180.0-1093.0) 0.42
TNF-α(pg/ml)
induced 0.4(0-1.9) 1.5(0-4.8) 0.34 0.00(0.00-2.5) 1.6(0-4.2) 0.14 2.3(0.0-5.1) 3.2(0.7-24.3) 0.24
spontaneous 0.9(0-3.2) 3.3(0.3-7.4) 0.20 0.5(0.0-4.5) 2.4(0.8-7.4) 0.18 6.43.7-14.0 7.9(2.1-173.9) 0.69
IL-18(pg/ml)
induced 9.0(0.9-19.3) 8.4(4.1-25.6) 0.58 10.6(2.4-14.9) 6.3(4.1-25.6) 0.91 5.04(0.0-13.6) 4.2(0.6-10.1) 1.0
spontaneous 2.9(0.5-14.8) 14.8(8.3-31.7) 0.01 8.8(1.0-15.1) 14.6(3.5-29.8) 0.24 10.4(5.0-13.9) 7.0(2.7-25.2) 0.45
MIG(pg/ml)
induced 332.2(30.1-661.7) 806.3(110.5-1391.4) 0.15 121.8(41.2-897.0) 661.7(110.5-1314.3) 0.27 157.8(43.3-1714.8) 677.1(179.0-961.8) 0.54












Table 5 Relative FEV1 decline in % predicted during
sputum induction
Exacerbations Steady state p*
n = 63 n = 390
0.004
Median (IQR) 12.64(5.56-21.79) 18.75(11.11-25)
Mean (SD) 14.80(13.05) 18.51(11.44)
*Wilcoxon sign rank test.
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whether to induce or not during an exacerbation was based
on several subjective factors in addition to oxygen satur-
ation; most importantly patients’ willingness to be induced
and the clinicians’ evaluation regarding obstructivity. Thus,
it is impossible from this design to conclude that sputum
induction would be safe during all exacerbations.
Although more studies on the subject of whether spon-
taneous and induced sputum samples could be compared
was recommended already in 2002 [4], few studies have
yet been published. We have found one earlier report on
levels of IL-8 in spontaneous versus induced sputum that
showed no significant differences in IL-8 levels between
the two sputum types in COPD patients in stable state
[16]. Our study confirmed the results from this earlier
study, but in addition we were able to show that this is
true also during exacerbations. We have been unable to
find earlier reports on the relationship between levels of
inflammatory markers in spontaneous and induced
sputum for the remaining five inflammatory markers. To
our knowledge comparison of other inflammatory
markers in induced and spontaneous sputum sampled on
the same consultation has not been performed in patients
with obstructive pulmonary disease.
It has previously been shown that the sputum sampled
early during induction has a different consistency and
cell composition than sputum sampled late in the induc-
tion [24,25]. It is likely that more central airways are sam-
pled early, and would thus most resemble spontaneous
sputum. Thus, induced sputum is likely to sample a more
distal airways environment than spontaneous sputum.
Central and distal airways differ by epithelial components
[26], distribution of immune cells [27,28], and possibly re-
spiratory microbiome [29]. Thus, it is theoretically rather
likely that levels of inflammatory markers differ between
spontaneous and induced sputum samples. However, one
can argue that spontaneous sputum could be a favorable
alternative to induced sputum when patients find induc-
tion uncomfortable, or the safety of the induction is uncer-
tain, and enable sampling in primary healthcare settings
where induction is rarely if ever performed to our know-
ledge. Cell viability in spontaneous sputum has in some
studies been shown to be poorer than in induced sputum
samples [15,16]. Such was not the case in our samples,where viability was as good in the spontaneous samples as
in the induced samples. In our study the time from collec-
tion to processing was usually very short, which could
explain the high viability.
Although agreement for individual measurements was
low, measuring levels of inflammatory markers in spon-
taneous sputum could have value for instance in serial
measurements of spontaneous sputum, something our
study is not equipped to assess. Also, although compari-
sons of inflammatory markers between spontaneous and
induced sputum is invalid for some markers, they may
be valid for others.
There are still sparse data on the safety on induction
in patients with severe COPD during exacerbations, and
in several studies sputum induction is performed during
exacerbation without the published reporting on poten-
tial adverse effects on the procedure [3,30,31].
In our study we found statistical differences in FEV1%
predicted decline between patients with moderate and
severe/very severe COPD only during steady state, while
disease severity did not affect the decline during exacerba-
tions. No adverse events were registered during either the
steady state or during exacerbations. This is in accordance
with other reports [7,11], but we expand by including pa-
tients with severe/very severe COPD. However, it should
be stressed that necessary precautions need to be taken
such as having access to acute rescue medications, and
that all inductions only should be performed by trained
medical personnel [32].
The results from the current study point toward a ne-
cessity for reporting on sampling methods when consider-
ing inflammatory markers in sputum samples collected
from COPD patients both during the steady state and dur-
ing acute exacerbations as the agreement was generally
low as assessed by Bland & Altman’s 95% limits of agree-
ment. Whether levels of inflammatory markers can be
compared between spontaneous and induced sputum
samples likely differ by each inflammatory marker in ques-
tion, and should be addressed within each study. In cases
where induced sputum sampling is impossible, spontan-
eous samples may have value if compared with other
spontaneous samples.Abbreviations
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